Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

New England Journal of Medicine

Volumn 344, Issue 25, 2001, Pages 1888-1894

  Topol, Eric J ^a   Moliterno, David J ^a   Herrmann, Howard C ^b   Powers, Eric R ^c   Grines, Cindy L ^d   Cohen, David J ^e   Cohen, Eric A ^f   Bertrand, Michel ^g   Neumann, Franz Josef ^h   Stone, Gregg W ⁱ   Dibattiste, Peter M ^j   Demopoulos, Laura ^j   Yakubov, Steven J ^k   Delucca, Paul T ^j  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

^e Beth Israel Deaconess Hospital   (United States)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ LENOX HILL HOSPITAL   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

^k RIVERSIDE METHODIST HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; THROMBOCYTOPENIA;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; THROMBOCYTOPENIA; TYROSINE;

EID: 0035927988     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200106213442502     Document Type: Article

References (27)

1. Stent scrutiny
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
3. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
4. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
5. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
6. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
7. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
8. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
9. Frontiers in interventional cardiology
10. Platelet GPIIb-IIIa blockers
11. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: Rationale and design of the TARGET study
12. Thrombolysis in Myocardial Infarction (TIMI) Trial - Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
13. Noninferiority trials
14. Some of the issues in the design and analysis of equivalence trials
15. A useful testing strategy in phase III trials: Combined test of superiority and test of equivalence
16. 3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor
17. 3 integrin blockade on leukocyte transmigration in vivo
18. Chimeric 7E3 Fab (Reo-Pro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty
19. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction
20. Randomized, doubleblind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasry
21. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
22. Recognition of the importance of embolization in atherosclerotic vascular disease
23. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
24. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
25. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
26. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban